Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours

Clinical Drug Investigation

Volumn 26, Issue 12, 2006, Pages 715-722

  Tropea, F ^a   Baldari, S ^b   Restifo, G ^b   Fiorillo, M T ^c   Surace, P ^c   Herberg, A ^b  

^a Department of Medical Oncology and Chemotherapy of Reggio Calabria ^*  (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Clinical Laboratory   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; SCINTIGRAPHY; TUMOR LOCALIZATION; UROGENITAL TRACT CANCER;

AGED; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOGRANIN A; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OCTREOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN;

EID: 33845451643     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626120-00005     Document Type: Article

References (21)

1. Taupenot L, Harper KL, O'Connor DT. Mechanisms of disease: the chromogranin-secretogranin family. N Engl J Med 2003; 348 (12): 1134-49
2. Nobels FRE, Kwekkeboom DJ, Bouillon R, et al. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28 (6): 431-40
3. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314 (18): 1145-51
4. Stridsberg M, Eriksson B, Öberg K, et al. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177: 337-41
5. Ferrari L, Seregni E, Bajetta E, et al. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 1999; 19 (4C): 3415-27
6. Sondenaa K, Sen J, Heinle F, et al. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004; 28 (9): 890-5
7. Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32 (3): 198-202
8. Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150 (3): 299-303
9. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13 (5): 653-68
10. Slooter GD, Mearadji A, Breeman WAP, et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001; 88 (1): 31-40
11. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12 (1): 109-17
12. Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13: 55-8
13. Giovanella L, Marelli M, Ceriani L, et al. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers 2001; 16: 268-72
14. Syversen U, Halvorsen T, Marvik R, et al. Neuroendocrine differentiation in colorectal carcinomas. Eur J Gastroenterol Hepatol 1995; 7: 667-74
15. Kimura N. Chromogranins in non-endocrine tumours. In: Helle KB, Aunis D, editors. Chromogranins: functional and clinical aspects. New York: Kluwer Academic/Plenum Publishers, 2000
16. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12 (1): 109-17
17. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155 (4): 1340-3
18. Deftos LJ, Nakada S, Burton DW, et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urol 1996; 48 (1): 58-62
19. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998; 42: 442-7
20. Samonakis DN, Moschandreas J, Arnaoutis T, et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002; 9 (4): 903-7
21. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002; 49 (47): 1245-50